.Pfizer and BioNTech start study to test combined COVID-19 and flu vaccine
The vaccine will combine the drugmakers' updated COVID-19 booster targeting the original strain of the COVID-19 virus from 2020 and omicron subvariants BA.4 and BA.5 with the influenza shot in hopes of simplifying the process for vaccinating individuals against both diseases at once.
The Phase 1 study aims to enroll 180 healthy volunteers in the United States ages 18 through 64 years old to assess the safety and efficacy of the vaccine. One participant already received the first dose of the combination shot this week.CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER The development of the combination shots comes as White House officials signal that COVID-19 shots are likely to be recommended on an annual basis, similar to the guidance for flu shots, to boost protection against the virus.
"In the absence of a dramatically different variants, we likely are moving towards a path with a vaccination cadence similar to that of the annual influenza vaccine, with annual updated Covid-19 shots matched to the currently circulating strains for most of the population," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and the chief medical adviser to the president, said in September.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer and BioNTech creating combined flu, COVID vaccineThe companies said that 180 U.S. adults ages 18-64 are part of the Phase 1 study. It administered the first dose of the combined vaccine this week.
Weiterlesen »
Pfizer, BioNTech start COVID-flu combination vaccine studyU.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Weiterlesen »
Pfizer, BioNTech launch phase 1 trial on combined COVID-19 and flu vaccinePfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday.
Weiterlesen »
Pfizer, BioNTech launch combo COVID-flu vaccine studyPfizer and BioNTech aim to enroll 180 U.S. volunteers between the ages of 18 and 64 for an early-stage trial to assess the safety, efficacy and optimal dosage.
Weiterlesen »
Pfizer-BioNTech testing combination flu-COVID-19 vaccineThe WHO estimates 290,000 to 650,000 people worldwide die of flu-related causes every year. About 1.1 million people in the U.S. have died from COVID-19.
Weiterlesen »